Inlexzo gets the nod in BCG-unresponsive non-muscle invasive bladder cancer, but the group has bigger plans.
ApexOnco Front Page
Recent articles
Pivotal data set the stage for slightly delayed US accelerated approval filing.
Casdatifan might have found its sweet spot, as part of a Cabometyx combo.
Ibtrozi breezes through FDA review and gives Nuvation its first approval.
A new phase 3 could see ivonescimab challenge AstraZeneca’s Imfinzi in limited-stage disease.
AVZO-023 follows AVZO-021 into clinical trials.
The move follows promising but early data presented at ASCO.
A phase 2/3 study might show whether teliso-A can do better than teliso-V.
